Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | CASP6 | P55212 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | DTYMK | P23919 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3260821 | 0.89 | TDP1 (0.53) | TDP1L3MBTL1CASP6TSHRCA1 | |
| SCHEMBL11644545 | 0.88 | LMNA (0.56) | TDP1L3MBTL1CASP6TSHRCA1 | |
| SCHEMBL28811434 | 0.88 | TDP1 (0.51) | TDP1L3MBTL1CASP6TSHRCA1 | |
| SCHEMBL16862931 | 0.88 | TDP1 (0.52) | TDP1L3MBTL1CASP6TSHRCA1 | |
| SCHEMBL21749965 | 0.88 | TDP1 (0.51) | TDP1L3MBTL1CASP6TSHRCA1 | |
| SCHEMBL4849618 | 0.87 | TDP1 (0.55) | TDP1L3MBTL1CASP6TSHRCA1 | |
| Pyridine SCHEMBL6828072 | 0.86 | L3MBTL1 (0.54) | TDP1L3MBTL1CASP6TSHRCA1 | |
| Pyridine SCHEMBL29674762 | 0.86 | L3MBTL1 (0.54) | TDP1L3MBTL1CASP6TSHRCA1 | |
| SCHEMBL1554602 | 0.86 | TDP1 (0.75) | TDP1L3MBTL1CASP6TSHRCA1 | |
| SCHEMBL29163865 | 0.83 | TDP1 (0.51) | TDP1L3MBTL1CASP6TSHRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5372816-A | Enzyme inhibitor for trehalase; insecticide | SUNTORY LIMITED (JP) | 1994-12-13 | — | — | US | claimed |
| EP-0414914-B1 | NEW SUBSTANCE TREHALOSTATIN AND PRODUCTION THEREOF | SUNTORY LTD (JP) | 1994-05-11 | — | — | EP | claimed |
| EP-0414914-A1 | NEW SUBSTANCE TREHALOSTATIN AND PRODUCTION THEREOF | SUNTORY LIMITED (JP) | 1991-03-06 | — | — | EP | claimed |
| US-3953297-A | Determination of amylase | PIERCE CHEMICAL COMPANY (US) | 1976-04-27 | — | — | US | claimed |
| JP-4125813-A | — | — | None | — | — | JP | disclosed |
| US-11772085-B2 | Far superior oxidation catalysts based on macrocyclic compounds | CARNEGIE MELLON UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| EP-1423115-B9 | ANTIANGIOGENIC ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | CHILDRENS MEDICAL CENTER (US) | 2009-09-02 | — | — | EP | disclosed |
| US-7566556-B2 | Enhancing enzyme thermostability by mixing with sorghum liquor waste | ACADEMIA SINICA (TW) | 2009-07-28 | — | — | US | disclosed |
| EP-1423115-B1 | ANTIANGIOGENIC ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | CHILDRENS MEDICAL CENTER (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20070105903-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | CELGENE CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-7153867-B2 | Use of nitrogen substituted thalidomide analogs for the treatment of macular degenerator | CELGENE CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1423115-A4 | SYNTHESIS AND ANTI-TUMOR ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | CHILDRENS MEDICAL CENTER (US) | 2006-08-16 | — | — | EP | disclosed |
| US-5372816-A | Enzyme inhibitor for trehalase; insecticide | SUNTORY LIMITED (JP) | 1994-12-13 | — | — | US | disclosed |
| EP-0414914-B1 | NEW SUBSTANCE TREHALOSTATIN AND PRODUCTION THEREOF | SUNTORY LTD (JP) | 1994-05-11 | — | — | EP | disclosed |
| US-5169778-A | Culture which produces insecticidal enzyme inhibitor for glucohydrolases | SAWAO MURAO (JP) | 1992-12-08 | — | — | US | disclosed |
| US-5169778-A | Culture which produces insecticidal enzyme inhibitor for glucohydrolases | SAWAO MURAO (JP) | 1992-12-08 | — | — | US | disclosed |
| JP-H04125813-A | MAGNETIC RECORDING MEDIUM | SONY CORP | 1992-04-27 | — | — | JP | disclosed |
| EP-0414914-A1 | NEW SUBSTANCE TREHALOSTATIN AND PRODUCTION THEREOF | SUNTORY LIMITED (JP) | 1991-03-06 | — | — | EP | disclosed |
| WO-1990010010-A1 | NEW SUBSTANCE TREHALOSTATIN AND PRODUCTION THEREOF | MURAO SAWAO (JP) | 1990-09-07 | — | — | WO | disclosed |
| US-3953297-A | Determination of amylase | PIERCE CHEMICAL COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11772085-B2 | Far superior oxidation catalysts based on macrocyclic compounds | SOD1, ME3, ME2 | TDP1 2577/4885L3MBTL1 387/4885CASP6 3710/4885 |
| US-20070105903-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | VEGFA, FLT4, FLT1 | TDP1 2625/4885L3MBTL1 2607/4885CASP6 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.